医学
斑秃
食品药品监督管理局
皮肤病科
类风湿性关节炎
临床试验
药方
2019年冠状病毒病(COVID-19)
重症监护医学
药理学
内科学
疾病
传染病(医学专业)
作者
Eman Ali,Rabia Owais,Ayesha Sheikh,Asim Shaikh
标识
DOI:10.1016/j.amsu.2022.104157
摘要
Olumniant (Barcitinib) has gained swift approval by the Food and Drug Administration (FDA) as a promising medication for the treatment of adults with severe Alopecia Areata. This drug has proven to be effective for various conditions including Covid-19 and Rheumatoid Arthritis as well as being found to be less costly and minimally invasive, with no need for post-operative management. However, its use has some considerable potential implications before its prescription can be made commonplace. Therefore, more trials need to be conducted to establish a more rigid safety profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI